Molecure has published its financial report for 2023 - the company has significantly accelerated the development of its clinical and pre-clinical programmes and plans to make strong progress in research in 2024 and 2025
We initiated clinical trials of our drug candidate, which was discovered and brought into clinical trials for cancer patients by Molecure.
- We initiated clinical trials of our drug candidate, which was discovered and brought into clinical trials for cancer patients by Molecure.
- In 2023, our focus was also on preparing for a Phase II clinical trial for OATD 01, Molecure's flagship clinical programme.
- We are very pleased to report that the first patient has started dosing in a clinical trial at a clinical site in the UK.
- The Company plans to obtain further grants for projects within the framework of the pipeline developed so far.